Ezetimibe

BOSTON — Hepatitis C infection was prevented or rapidly cured in transplant recipients who received organs from donors infected with the virus following combined treatment with ezetimibe and direct-acting antiviral therapy, according to study results presented at The Liver Meeting 2019.

Evolocumab in addition to standard of care for the treatment of hypercholesterolemia was shown to have consistent, significant LDL-lowering ability after 5 years of treatment, according to final data from the OSLER-1 trial.

CHICAGO — The 2018 Guideline on the Management of Blood Cholesterol, published by the American College of Cardiology and the American Heart Association in collaboration with other societies, offered a number of pointers for clinicians to diagnose, treat and manage patients with elevated cholesterol.

PARIS — Inclisiran, an investigational cholesterol-lowering therapy in the small-interfering RNA class, achieved durable and potential LDL reduction with twice-yearly injections, according to new data from the ORION-11 study.

A biomarker-based approach may effectively identify a gradient of risk among post-ACS patients who would most benefit from the addition of ezetimibe to statin therapy.

Regeneron announced top-line results of a phase 3 study showing that evinacumab, its investigational angiopoietin-like 3 antibody, reduced LDL by 49% in patients with homozygous familial hypercholesterolemia who were taking other medications.

The American Heart Association and the American College of Cardiology, in collaboration with multiple other societies, recently published two highly significant documents in the field of preventive cardiology.

It is well known that HMG-CoA reductase inhibitors reduce LDL, a surrogate marker in atherosclerotic disease, as well as primary and secondary CHD events, the need for revascularization and ischemic stroke.